‘Life-changing': Viral TikTok migraine hack that actually works
But one young woman has revealed the bizarre, unlikely hack that works for her — even when pain meds don't.
And a neurologist told The New York Post her method actually makes sense.
In a video which has had over 36 million views on TikTok, Tilly Walker (@toeatilly) lies in bed, face up, while balancing a full bottle of Evian water on her forehead.
'How I sleep, as no medicine helps my migraines, but balancing a water bottle on my head stops the pain,' she explained.
She said figuring it out has been 'life-changing knowledge.'
While this basic balancing act may seem like too simple a solution, experts say there's science to support it.
'There is a long history of using pressure on the forehead to relieve pain, from placing stones on the body to tying a handkerchief tight on the head,' Noah Rosen, MD, a neurologist and director of the Northwell Headache Center, told The Post.
'Some of the benefits from this may be Diffuse Noxious Inhibitory Control where a strong stimulus may suppress another one, like rubbing around a paper cut.
'There have even been devices like the Nerivio patch, which try to use a stimulus on the arm to reduce headaches.'
For Tilly, the pressure is key — she noted that the bottle has to be full for it to work.
And commenters have pointed out how absolutely desperate she must have been when she stumbled upon the trick.
'This is the sort of thing that only a person with a migraine could think of trying,' wrote one.
But she's not alone — several commenters have admitted to using the water bottle method as well.
'GIRL!!! I thought I was the only one doing it, it works so well,' one said.
Rosen noted that the bottle may also function as a mindfulness tool, offering further relief.
'Focusing on the bottle rather than the pain may help to be in the moment rather than focusing on a discomforting abstraction,' he explained.
Other commenters have chimed in to share their own weird recommendations for alleviating a severe headache, including consuming raw mimosa flowers, wearing an eye mask, applying potato slices to the forehead, submerging feet in hot water, and getting a daith or inner ear piercing.
Other cures include the viral 'migraine meal', which consists of a large Coca-Cola and a large order of fries from McDonald's.
One viral video with more than 3.8 million views shows a girl at the fast-food chain's drive-through with overlay text reading, 'Trying McDonald's chips and a Diet Coke because I've had a headache for 48 hours and TikTok said it would help.'
Doctors say the caffeine in soda can operate as a nerve disrupter, a substance that affects nerve activity and blood flow to the brain.
Sometimes, this disturbance works positively, but it's a roll of the dice or a draw of the straw, as caffeine consumption can also trigger migraines.
In addition, the salt and sugar present in the 'migraine meal' can constrict blood vessels and also impact blood flow to the brain.
Aside from fast food, experts have seen success in using magnesium to prevent migraines.
For his part, Rosen says the water bottle hack is a generally safe choice for migraine sufferers so long as they take precautions.
'I would say if you do it, be careful and don't let it hurt your eyes, nose or spill on you!'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
7 hours ago
- News.com.au
Health Check: Breast cancer patients are the winners in Imagion's SQUID game
Imagion shares surge 35% on the back of a fruitful FDA trial meeting Biome's offshore push reaps rewards FDA introduces pricing test in new fast-track drug review program Shares in molecular diagnostic imaging house Imagion Biosystems (ASX:IBX) are on a roll again, after positive feedback from the US Food & Drug Administration (FDA) about the conduct of a phase II breast cancer diagnostics trial. In a video hookup, FDA reps did not raise any concerns about the proposed study, having requested earlier clarification about its 'structuring and operation'. Imagion plans to file an Investigational New Drug application – permission to start a trial – with the FDA in the current quarter. While the chinwag may seem a formality, it comes at a time when the FDA's intentions are increasingly difficult to divine. 'Our clinical team was pleased and very encouraged with the level of engagement we had with the reviewers,' said Imagion executive chairman Bob Proulx. 'The fact that senior staff participated on the call is a sign the agency is interested in … our plans for the phase II trial and the potential impact our technology may have on breast cancer diagnosis and staging.' The trial will road test Imagion's Magsense tech, for detecting Her-2 positive breast cancer. Magsense involves injecting nanoparticles labelled with cell-specific targeting antibodies, contained within an iron oxide solution. SQUID game with a happier ending The technology is known as super-paramagnetic relaxometry. It may sound like something out of a Nimbin shopfront – but it's totally legit. The nanoparticles are subject to a low magnetic pulse, with their location detected by an ultra-sensitive super-conducting quantum interference device. Yep, that's a SQUID. The nanoparticles attached to the cancer cells lose their magnetism more slowly than the unattached ones, acting as a magnetic beacon. The open-label trial will be carried out across multiple US sites. After a rough start to 2025, Imagion shares have risen 80% over the past month. Syntara enrols first burns scar patient Syntara (ASX:SNT) says the first patient in a phase Ic study to treat keloid scars – an unsightly and painful legacy of burns – has been dosed. Dubbed Satellite, the study evaluates Syntara's topical lysyl oxidase inhibitor SNT-6302. The trial was initiated by the investigator, famous Perth burns surgeon Professor Fiona Wood (in partnership with the University of Western Australia). The open-label, placebo-controlled study will enrol up to 20 participants, with active keloids measuring between 5-25cm2. An earlier study showed a 30% reduction in collagen content and improved scar vascularisation – both good things. The patients will apply SNT-6302 four times a week over three months. In truth, Syntara focuses on its flagship trial for myelofibrosis. But the company values the market for burns scars at US$3.5 billion globally, which is nothing to sneeze at. For Biome, there's no place like offshore Following an earlier update, probiotics and complementary medicines provider Biome Australia (ASX:BIO) reported $1.5 million of overseas revenue for the year to June 30, up 69%. The company recently secured three 'prominent strategic distribution partnerships' in three markets: Ireland, NZ and Canada. Irish eyes are smiling after a hook up with the Emerald Isle's pharmacy wholesaler and retailer, Uniphar. In NZ, Biome has entered a new distribution tie-up with pharmacy wholesaler Propharma, owned by EBOS Group (ASX:EBO). EBOS also owns pharmacy wholesaler Symbion, a key Biome distributor in Australia. In Canada, Biome has secured 'multiple high-value agreements with prominent pharmacy and health food retail groups'. On July 1 Biome reported overall record sales revenue of $18.4 million for the year, up 41%. The company also posted record June quarter revenue of $5 million, up 33%. The company also expects another quarter of positive underlying earnings for the quarter, translating to an inaugural full year net profit. Biome is also on track to meet its target of $75 million of annual revenue by 2027. Biome develops, licences and commercialises 'evidence based' live biotherapeutics – a.k.a probiotics. The company says its Activated Probiotics line can treat 'various health concerns' including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome. Biome shares have lost 15% of their value over the last year but have improved 24% over the last month. FDA links new vouchers with drug prices The FDA is taking a new line in the drug pricing debate by linking drug affordability with a new fast-track drug approval mechanism. Known as the Commissioner's National Priority Voucher (CNPV), the scheme will run alongside the existing Priority Review Voucher (PRV) program. The CNPV could cut approval times from up to a year, to as little as a month. At least that's for drugs that address criteria such as addressing a health crisis, innovating or increasing US national security. Getting a blockbuster drug to market a few months earlier can mean billions of dollars of extra sales. FDA new head honcho Marty Makary says drugs for type 1 diabetes, neurodegenerative diseases and advanced cancers could fit the bill. Last month's CNPV reveal did not mention pricing. Now, Makary says the agency will consider drug affordability when granting new vouchers. Given drug makers and gatekeepers usually determine drug prices post launch, it's not clear how the FDA could take them into account. PRVs are valuable – and Neuren can vouch-er for it The FDA will continue the PRV program, unchanged. The agency bestows PRVs on drug developers who get selected therapies to market, such as a rare childhood disease. PRV recipients usually sell them to a third party. The developer of the FDA approved Rett syndrome drug Daybue, Neuren Pharmaceuticals (ASX:NEU) enjoyed a US$50 million windfall after its US partner Acadia sold the attached PRV for US$150 million. However, the CNPVs will be non-transferable. In the meantime, President Trump plans to revive a 'most favoured nation' mechanism. This ties the price of a certain drug in the US to that imposed in the cheapest western country. Trump has also threatened a 200% tariff on imported drugs, which in theory would drive drug prices higher. So, it's a balancing act – rather like playing off Vladimir and Volodymyr.

ABC News
10 hours ago
- ABC News
US health overhaul to be unveiled
A controversial health movement's gaining traction in the highest levels of US politics and it's about to release its first national strategy. Next month, the Make America Healthy Again Commission, a federal taskforce created by President Trump and his Health Secretary, Robert F Kennedy Jr., is expected to unveil a sweeping plan to overhaul American health and food policy.

ABC News
a day ago
- ABC News
Making America Healthy Again? The inside story of how the 'wellness revolution' won the White House
On Foreign Correspondent an exclusive interview with Donald Trump's former wife, Marla Maples about the pivotal role she is playing in the wellness revolution now controversially reshaping America's health system. When Robert F Kennedy Jr, a member of the famed Democrat dynasty and prominent vaccine sceptic, joined Donald Trump's MAGA movement, many people were shocked. But in the online world of wellness, the partnership came as no surprise. Reporter Naomi Selvaratnam reveals the back story to the movement, born out of pandemic-era distrust, which has now grown into a potent political force. Powered by mothers, wellness influencers and alternative health advocates, it's challenging Big Pharma, the food industry and government regulation. While America's appalling health statistics tell a troubling story, not everyone believes Make America Healthy Again holds the answers. Naomi also meets the doctors and scientists who are worried the movement is cover for a growing anti- vax agenda and will do little to solve the real health problems the country faces.